Lung Cancer Drugs Market Report 2026

The lung cancer drugs market size has grown strongly in recent years. It will grow from $52.98 billion in 2025 to $58.23 billion in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to high smoking prevalence, rising lung cancer incidence, widespread chemotherapy adoption, expansion of oncology hospitals, increased availability of generic cancer drugs.

The lung cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $88.06 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to growth in targeted and immunotherapy drugs, increasing lung cancer screening rates, rising healthcare expenditure in oncology, aging population, expansion of combination therapy approvals. Major trends in the forecast period include rising adoption of targeted lung cancer therapies, increased use of combination drug regimens, growing focus on early-stage lung cancer treatment, expansion of personalized treatment protocols, increasing hospital-based administration of oncology drugs.

The increasing prevalence of lung cancer is expected to propel the growth of the lung cancer drugs market in the coming years. Lung cancer is a serious and potentially fatal malignancy that necessitates timely and effective interventions, including chemotherapy, targeted therapies, immunotherapies, and combination treatments to enhance survival outcomes. The rise in lung cancer cases is largely attributed to environmental pollution and exposure to carcinogens, along with genetic predisposition, which together can lead to lung cell mutations even in non-smokers. The growing incidence of lung cancer fuels demand for more effective treatment options that can extend life expectancy, slow tumor progression, and improve patients’ quality of life. For example, in January 2023, the American Cancer Society, a US-based voluntary health organization focused on eradicating cancer, estimated approximately 238,340 new lung cancer cases (117,550 in men and 120,790 in women) and about 127,070 lung cancer-related deaths (67,160 in men and 59,910 in women) for 2023. Consequently, the rising prevalence of lung cancer is driving the expansion of the lung cancer drugs market.

Major companies in the lung cancer drugs market are emphasizing product innovation and new formulations, such as chemotherapy-free combination therapies targeting EGFR mutations, to improve treatment effectiveness, lower systemic toxicity, and enhance quality of life for patients with advanced non-small cell lung cancer (NSCLC). These therapies support precision oncology strategies, providing targeted inhibition of specific molecular pathways that drive tumor growth. For example, in August 2024, Johnson & Johnson, a US-based pharmaceutical company, obtained U.S. FDA approval for Rybrevant plus Lazcluze as a first-line, chemotherapy-free therapy for patients with EGFR-mutated advanced NSCLC. This combination therapy is designed to deliver dual inhibition of EGFR and MET pathways, offering stronger anti-tumor effects while reducing exposure to traditional chemotherapy side effects. This approval highlights a rising trend in the lung cancer market toward personalized, targeted treatment approaches that enhance patient outcomes and experience by decreasing reliance on conventional chemotherapy.

In January 2024, Bristol-Myers Squibb, a US-based biopharmaceutical company, acquired Mirati Therapeutics for approximately $4.8 billion. Through this acquisition, Bristol-Myers Squibb intends to strengthen its lung cancer drug portfolio by incorporating Mirati’s targeted therapies, including KRAS G12C inhibitors, to offer innovative treatment options for patients with advanced and metastatic lung cancer. Mirati Therapeutics, a US-based biotechnology company, focuses on the development of precision oncology therapies and has a strong track record in lung cancer drug development.

Major companies operating in the lung cancer drugs market are Bristol-Myers Squibb Company, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Celgene Corporation, Mylan N.V., Ono Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Ziopharm Oncology Inc., Menarini Group, AstraZeneca PLC, AbbVie Inc., Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eli Lilly and Company Inc., Johnson & Johnson, Amgen Inc., Array BioPharma Inc., Astellas Pharma Inc., Clovis Oncology Inc., Eisai Co. Ltd., Exelixis Inc., Genentech Inc., Gilead Sciences Inc., Incyte Corporation, Ipsen Biopharmaceuticals Inc., Kyowa Kirin Co. Ltd., Loxo Oncology Inc., MedImmune LLC.

North America was the largest region in the lung cancer drugs market in 2025. Middle East is expected to be the fastest-growing region in the lung cancer drugs market during the forecast period. The regions covered in the lung cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lung cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the lung cancer drugs market by increasing the cost of imported oncology APIs and biologics used in targeted therapies and combination treatment regimens. These impacts are strongest in advanced drug segments and hospital procurement channels, where pricing sensitivity and supply continuity are critical. Regions such as North America and Asia Pacific have experienced higher input costs due to reliance on global oncology supply chains. Rising tariff related expenses have influenced procurement planning, reimbursement discussions, and inventory strategies in oncology care settings. At the same time, tariffs have encouraged domestic oncology drug manufacturing, expanded local production capacity, and reduced long term supply dependency.

The lung cancer drugs market research report is one of a series of new reports that provides lung cancer drugs market statistics, including lung cancer drugs industry global market size, regional shares, competitors with a lung cancer drugs market share, detailed lung cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer drugs industry. This lung cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lung cancer drugs are anti-angiogenic medications used to treat lung cancer. Lung cancer is a type of cancer that reduces the lungs' ability to deliver oxygen to the bloodstream due to the uncontrolled growth of tissue in the lungs. Some of the potential treatments for lung cancer include surgery, chemotherapy, radiation therapy, and targeted therapy. Depending on the size of the tumor cells, lung cancer is generally classified into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).

The main categories of lung cancer are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Small cell lung cancer is a fast-growing form of cancer that develops in the lung tissues. By the time it is diagnosed, small cell lung cancer has often spread (metastasized) beyond the lungs. This type of cancer also has a higher likelihood of returning after treatment compared to other forms of lung cancer. The various drugs include Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, and others, and they are utilized across settings such as hospitals, clinics, and more.

The lung cancer drugs market consists of sales of bevacizumab, atezolizumab, and ramucirumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.